Delivery of physiologically active compounds through an inhalation route
First Claim
1. A method of treating anxiety, vertigo, alcohol withdrawal, nicotine withdrawal, sedation, hot flashes, peptic ulcers or for testosterone replacement therapy, hormone replacement therapy, or prevention of pregnancy comprising administering a therapeutic amount of an physiologically active compound condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% physiologically active compound degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of physiologically active compounds through an inhalation route. Specifically, it relates to aerosols containing physiologically active compounds that are used in inhalation therapy. In a method aspect of the present invention, a physiologically active compound is delivered to a patient through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises a physiologically active compound, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% physiologically active compound degradation products. In a kit aspect of the present invention, a kit for delivering a physiologically active compound through an inhalation route is provided which comprises: a) a thin coating of a physiologically active compound composition and b) a device for dispensing said thin coating as a condensation aerosol.
102 Citations
28 Claims
-
1. A method of treating anxiety, vertigo, alcohol withdrawal, nicotine withdrawal, sedation, hot flashes, peptic ulcers or for testosterone replacement therapy, hormone replacement therapy, or prevention of pregnancy comprising administering a therapeutic amount of an physiologically active compound condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% physiologically active compound degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
- View Dependent Claims (2, 3, 4, 5, 6)
-
7. A method of treating anxiety, vertigo, alcohol withdrawal, nicotine withdrawal, sedation, hot flashes, or peptic ulcers or for testosterone replacement therapy, hormone replacement therapy, or prevention of pregnancy comprising administering a therapeutic amount of a chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
- View Dependent Claims (8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
18. A method of administering a physiologically active compound to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of a physiologically active compound having less than 5% physiologically active compound degradation products and an MMAD less than 3 microns wherein the peak plasma concentration of the physiologically active compound is achieved in less than 0.1 hours.
-
19. A method of administering chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine having less than 5% chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine degradation products and an MMAD less than 3 microns wherein the peak plasma drug concentration of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine is achieved in less than 0.1 hours.
-
20. A kit for delivering a drug aerosol comprising:
-
a) a thin coating of a physiologically active compound composition and b) a device for dispensing said thin coating as a condensation aerosol. - View Dependent Claims (21, 22, 23, 24, 25, 26, 27, 28)
-
Specification